Pyxis Oncology, Inc. (PYXS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.98
- As of
Kresmion compiles this page from PYXS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Pyxis Oncology, Inc. (PYXS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
See the full PYXS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PYXS on one page. Preview it with sample data, then open it live with a free account.
Preview the PYXS dossierActive events for PYXS
- mediumEarnings below estimates
Q2-2026: Missed consensus by 11.0%, EPS $-0.40 vs $-0.3604 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 75% of PYXS (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 83% of PYXS (2026Q1)
- mediumEarnings above estimates
Q2-2025: Beat consensus by 16.4% - EPS $-0.3 vs $-0.3587 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 15.6% - EPS $-0.29 vs $-0.3434 estimate
FREE, NO ACCOUNT
Every event on PYXS, as it fires
New filings, 13F moves and cross asset events on PYXS land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PYXS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 747324101 · 2026Q2 | $2.3M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 747324101 · 2026Q2 | $701K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 747324101 · 2026Q2 | $253K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 747324101 · 2026Q2 | $142K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 747324101 · 2026Q2 | $112K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PYXS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PYXS against its peers
PYXS's operating margin of -609.2% ranks in the 42nd percentile of 17 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | PYXS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 13.9M USD | 19.4M USD | 47 | 17 |
| Gross margin | 82.8% | 64.3% | 56 | 7 |
| Operating margin | -609.2% | -221.7% | 42 | 17 |
| Net margin | -574.5% | -233.7% | 34 | 18 |
| Return on equity | -149.1% | -33.5% | 15 | 23 |
Peers (24): ALEC, PLX, CAMP, SION, NAGE, EVMN, BBOT, YARW, RNAC, ELDN, ZNTL, CGEN, KROS, DTIL, WHWK, PRQR, IKT, XGN, ACOG, IVVD, SLGL, KRRO, LXEO, IFRX. Left out: SCNLD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (PYXS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PYXS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PYXS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.